Insulin detemir reduces the risk of hypoglycaemia at all levels of HbA1c compared to NPH insulin in the context of basal-bolus therapy for type 1 diabetes

被引：0

作者：

Jones, DR

Kim, H

Heller, S

Clauson, P

机构：

[1] Royal Surrey Cty Hosp, Dept Endocrinol & Diabet, Guildford, Surrey, England

[2] Univ Sheffield, Sheffield, S Yorkshire, England

[3] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark

来源：

DIABETOLOGIA | 2005年 / 48卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

243

引用

页码：A92 / A93

页数：2

共 50 条

[11] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Palmer, AJ
Roze, S
DIABETES, 2005, 54 : A609 - A609
[12] Insulin Detemir Reduces Hypoglycemic Risk at Comparable HbAfc Values Compared to NPH Insulin in Patients with Type 1 Diabetes
Hermansen, Kjeld
Heller, Simon
Andersen, Marc
Russell-Jones, David L.
DIABETES, 2009, 58 : A529 - A530
[13] Treatment with insulin detemir once daily is associated with lower risk of hypoglycemia at similar levels of HbA1c compared to once-daily NPH insulin in subjects with type 1 diabetes mellitus
Shaw, Jonathan E.
Larsen, Jens
Pedersen, Claus B.
Tang-Fui, Serge
DIABETES, 2008, 57 : A595 - A595
[14] Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes
Robertson, K. J.
Schoenle, E.
Gucev, Z.
Mordhorst, L.
Gall, M. -A.
Ludvigsson, J.
DIABETIC MEDICINE, 2007, 24 (01) : 27 - 34
[15] LOWER TREATMENT COSTS WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN TYPE 1 DIABETES PATIENTS TREATED WITH A BASAL-BOLUS REGIMEN IN GERMANY
Wiesner, T.
Schaedlich, P. K.
Dippel, F. W.
Koltermann, K.
Hagenmeyer, E. G.
VALUE IN HEALTH, 2010, 13 (07) : A294 - A294
[16] Compared to NPH insulin, insulin detemir is associated with a superior efficacy: tolerability profile and reduced excess weight gain when used in basal-bolus therapy for children and adolescents with type 1 diabetes
Robertson, Kenneth
Gall, Mari Anne
HORMONE RESEARCH, 2006, 65 : 57 - 57
[17] Insulin detemir and insulin aspart:: a promising basal-bolus regimen for type 2 diabetes
Raslová, K
Bogoev, M
Raz, I
Leth, G
Gall, MA
Hancu, N
DIABETES RESEARCH AND CLINICAL PRACTICE, 2004, 66 (02) : 193 - 201
[18] Efficacy of Insulin Degludec as Basal-Bolus Therapy After Switching from Insulin Glargine or Insulin Detemir in Young Persons with Type 1 Diabetes
Urakami, Tatsuhiko
Habu, Masako
Okuno, Misako
Suzuki, Junichi
Takahashi, Shori
DIABETES, 2014, 63 : A323 - A323
[19] Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart
Vague, P
Selam, JL
Skeie, S
De Leeuw, I
Elte, JWF
Haahr, H
Kristensen, A
Draeger, E
DIABETES CARE, 2003, 26 (03) : 590 - 596
[20] Lower rate of hypoglycaemia but comparable glycaemic control with insulin detemir compared to NPH insulin in patients with type 1 diabetes
Hermansen, K.
Heller, S.
Andersen, M.
Russell-Jones, D. L.
DIABETOLOGIA, 2009, 52 : S359 - S359

← 1 2 3 4 5 →